V

Varda Space

In-orbit manufacturing with reentry return services

Flight Software Intern

Year-roundPosted on 3/24/2026
$37/hr+ Housing stipend + Commuter benefit
Internship
El Segundo, CA, USA
In PersonRelocation support available for new hires.
No H1B Sponsorship

About the job

Requirements
  • Proficiency in C++ and/or Python.
  • Actively enrolled in an accredited undergraduate or graduate program during the internship term.
  • Understanding of core computer science fundamentals including data structures, algorithms, and operating systems.
  • Ability to debug complex software issues and comfort working in Linux environments.
Responsibilities
  • Use first-principles reasoning to approach problems and justify design tradeoffs.
  • Build Python and/or C++ tools, services, and libraries that interface with flight and ground systems, emphasizing correctness, determinism, and observability.
  • Contribute to automation for simulation, hardware-in-loop, and scenario-based testing.
  • Debug issues that cross abstraction boundaries, including OS behavior, networking, timing, and hardware-software interactions.
  • Collaborate across flight software, embedded systems, mission operations, and test teams; communicate clearly, ask clarifying questions early, and seek support when needed.
Desired Qualifications
  • Familiarity with systems fundamentals including concurrency, networking, performance, and reliability.
  • Exposure to real-time embedded development or safety-critical software, and a working knowledge of math and physics.
  • Experience may come from coursework, personal projects, community college, bootcamps, open-source contributions, internships, or self-driven learning. We care more about your fundamentals, curiosity, and engineering approach than how you acquired them.
  • Participation in any project work. Whether robotics, rocketry, capstone projects, personal builds, lab work, or open-source contributions. Focus on demonstrating an interest in understanding systems beneath abstraction layers.

About the company

Varda Space Industries provides in-space manufacturing services by operating production facilities in low Earth orbit and returning finished products to Earth using reentry capsules. Clients send materials or designs to Varda’s in-orbit production line, where microgravity enables manufacturing processes not possible on Earth, before the goods are sent back via capsules. The company builds end-to-end in-orbit infrastructure, including production equipment and reliable reentry systems, to make low Earth orbit more accessible for multiple industries. Its goal is to industrialize low Earth orbit by enabling production in space and bringing products back to Earth for commercial use.

Company Size

201-500

Company Stage

Series D

Total Funding

$609.5M

Headquarters

El Segundo, California

Founded

2020

Get referred to Varda Space

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Varda raised $251 million on September 30, 2026 at a $1.6 billion valuation.
  • It booked 28 launches through 2029, insulating supply after Falcon ride-share reductions.
  • United Therapeutics signed in May 2026, and Mikael Dolsten joined Varda's board in August.

What critics are saying

  • SpaceX Starfall launched June 23, 2026, threatening Varda's return-logistics business with scale.
  • About 70% of 2027 payload demand is government-based, exposing Varda to Pentagon budgets.
  • Australian recovery sites and FAA coordination constrain cadence; 2023 licensing delays already halted W-1.

What makes Varda Space unique

  • Varda completed six reentries by September 2026, proving repeatable orbital manufacturing and recovery.
  • Its FAA Part 450 license through 2029 lowers reentry friction versus one-off competitors.
  • Varda builds capsules and heat shields in El Segundo, controlling the full return stack.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Exciting team of professionals at the top of their field to working by your side

Working in El Segundo, CA - an awesome Southern California beach city with quick access to entertainment and outdoor activities

Equity in a fully funded space startup that is about to go through massive growth

Company parties and generally a fun atmosphere

401(k)

Unlimited PTO

Health insurance

Lunch and snacks provided on site. Dinners twice a week for those working late.

Parental leave

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↓ -2%

2 year growth

↓ -5%
BioSpace
Oct 2nd, 2026
Varda raises $251M to leverage gravity in space for drug production.

Varda raises $251M to leverage gravity in space for drug production. October 2, 2026 | Capitalizing on space's microgravity, the United Therapeutics-partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules. Varda Space Industries has raised $251 million to manufacture medicines in space for patients on Earth. Lux Capital and Natural Capital co-led the series D round for Varda, valuing the company at $1.6 billion, Reuters reported on Wednesday. Varda, which was set up in 2021 by former SpaceX engineer Will Bruey and Founders Fund partner Delian Asparouhov, has now raised $598 million in total since its founding. The California-based startup launched its first mission in 2023 and has completed six successful reentries. Varda has booked 28 launches with SpaceX and other providers between 2027 and 2029, Reuters reported on Wednesday. The support reflects the belief that Varda is "the first and only company delivering a real cadence of launches and reentries," Shahin Farshchi, partner at Lux Capital, said in a prepared statement. Space's lower levels of gravity, which make objects seem weightless, influence crystal formation in ways that could affect drug properties such as stability and bioavailability. Evidence of the microgravity's effect on drug molecules has fueled decades of research. NASA sponsored a report on the topic in 1978, and Merck's space station research informed its subcutaneous Keytruda formulation. With the cost of sending a kilogram to orbit falling 96% from 1960 to 2025 and forecast to drop further through 2040, one barrier to commercially viable drug production in space is lowering. Varda is among the companies seeking to capitalize on the shift. The company launches its capsules into orbit aboard commercial rockets, such as SpaceX's Falcon 9. The capsules contain equipment for processing pharmaceuticals in orbit. After completing processing, the capsule separates from the orbital satellite, returns to Earth and is recovered for analysis. Other groups have shown that a small quantity of space-grown crystals can support multiple terrestrial production batches. In May, United Therapeutics partnered with Varda to develop improved formulations of treatments for rare lung indications. The pact supports the exploration of "how space-based manufacturing could contribute to significant improvements for rare pulmonary disease treatments," United Therapeutics CEO Martine Rothblatt said in a statement at the time. Varda and United Therapeutics have competition in the race to discover and make drugs in orbit. Space Microgravity Development (SpaceMD), part of the space and defense technology company Redwire, has given former Merck researcher Paul Reichert a strategic advisory role as it pursues orbital research and manufacturing. SpaceMD has signed a contract for a mission using Starfall, SpaceX's recently launched in-space manufacturing program. And Voyager Technologies operates research facilities aboard the International Space Station. The company's capacity, which supports a microgravity-enabled drug discovery pact with Space LiinTech, will be enhanced next year with a system for automated drug screening. Nick is a freelance writer who has been reporting on the global life sciences industry since 2008.

PR Newswire
Oct 1st, 2026
Varda Space launches two spacecraft on single rocket, enters fleet operations phase

Varda Space Industries has launched two spacecraft on a single rocket for the first time, marking a shift to fleet operations. The company's W-8 and W-9 vehicles lifted off aboard SpaceX's Transporter-18 rideshare mission from Vandenberg Space Force Base. Both spacecraft carry payloads from government and commercial partners. W-8 hosts Canopy Aerospace & Defense's heat shield monitoring system and thermal protection materials funded by the Air Force Research Laboratory. W-9 carries a hypersonic navigation system and advanced heatshield materials from Syensqo. Varda has safely reentered six capsules since 2024. The dual launch demonstrates the company's increasing mission cadence as it scales orbital pharmaceutical processing and hypersonic reentry operations. The vehicles will be managed from Varda's expanded Mission Operations facility in El Segundo.

Pharmaceutical Technology
Oct 1st, 2026
Varda pockets $251m to back space-based pharma processing mission.

Varda pockets $251m to back space-based pharma processing mission. Varda secures this capital as drugmakers tout the potential of manufacturing in microgravity conditions to create differentiated medicines. Varda Space Industries has banked $251m in a Series D financing to scale its in-space pharmaceutical processing operations, as the industry increasingly recognises the potential of producing drugs in microgravity conditions. With cash provided by Lux Capital and Natural Capital, as well as contributions from other players like Kholsa Ventures and the Founders Fund, Varda plans to enhance the frequency and speed at which it can launch and return materials between Earth and orbit, as well as deepen its partnerships with the pharma industry. The company secured this funding, which brings its total capital raised to $598m, as it looks to debut the first space-made medicine on the pharmaceutical market. Unlike Earth-based drug processing, manufacturing in space is performed in zero-gravity conditions. By producing medicines in space without the constraints of gravity, Varda proposes that active pharmaceutical ingredients (APIs) can be crystallised in ways that are impossible on Earth - potentially allowing for the market entry of a new swathe of medicines with differential patient benefits. Thus far, Varda has already had some success in the space, with the company completing its first mission launch in 2023. Since then, the microgravity-led processing company has completed six successful re-entry missions. With its eyes on further expansion, Varda is also planning more than 12 more launches and re-entries up to 2028, as it looks to become the leading space life sciences company. "We started Varda with the conviction that the first product manufactured in space and consumed on Earth would be a pharmaceutical," commented Delian Asparouhov, co-founder and president of Varda. "This round gives us the resources to increase our cadence, deepen our pharmaceutical partnerships, and get closer to delivering the first medicine made in space," he added. Global governments bet on in-orbit medicines manufacturing. Varda secures this capital as space-based drug production garners increasing interest from global governments. This includes the UK government, which is actively looking to create a favourable regulatory environment for space-manufactured drugs in Britain by debuting a regulatory sandbox focused on re-entry. This is designed to streamline the licensing process for scaled in-orbit operations and facilitate the sector's growth. On top of these regulatory shifts, the British government has also financially backed UK-based space biotech startup, BioOrbit, which is currently running feasibility studies focused on crystallising biologics in-orbit to allow for the creation of home-administered cancer therapies. The Swiss government is also looking to be part of the action, as it recently joined forces with the UK to figure out how best regulators, investors and the government can harmoniously address and overcome current challenges linked to space manufacturing. Give your business an edge with its leading industry insights.

Traded
Sep 30th, 2026
Varda Space Industries raises $251M from ceo Will Bruey.

Varda Space Industries raises $251M from ceo Will Bruey. El Segundo-based Varda Space Industries, microgravity-enabled, raised $251M Series A+ from CEO Will Bruey. El Segundo-based Varda Space Industries, microgravity-enabled, raised $251M Series A+ from... Traded Editorial Varda Space Industries raises $251M in a series a+ from CEO Will Bruey.

PR Newswire
Sep 30th, 2026
Varda Announces $251 Million Series D to Scale Space-Based Pharmaceutical Processing

/PRNewswire/ -- Varda Space Industries announced a Series D fundraising round today, bringing the total amount of capital raised by the microgravity-enabled...

INACTIVE